Investor Relations

We at Auris Medical are dedicated to developing novel pharmaceutical therapies to protect hearing and to silence tinnitus.

Auris Medical is the leading pioneer in the emerging field of cochlear (inner ear) therapies. We have two projects in advanced clinical development:

AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss.

We have additional projects under development and are further strengthening our pipeline through collaborations with leading academic institutions in this field.

 

View more

 

Auris Medical AG Annual General Meeting
Thursday, April 13, 2017 10:00 a.m. CET
Description

Parkhotel Zug: Industriestrasse 14, Zug, Switzerland

Record Dates:

Holders of record: April 7, 2017

Street name holders: March 10,2017

Supporting Materials
Download Event Supporting Material Invitation to the Annual General Meeting of Shareholders
Download Event Supporting Material Annual Report on Form 20F
Download Event Supporting Material Standalone Financial Statements of Auris Medical Holding AG


Various statements that Auris Medical Holding makes on this website about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The terms 'may,' 'will,' 'could,' 'anticipate,' 'plan,' 'continue,' 'project,' 'intend,' 'estimate,' 'believe,' 'expect,' and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors.

In addition, any forward-looking statements represent the company's views only as of the date such statements are made and should not be relied upon as representing our views as of any subsequent date. While the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, even if its views change. Therefore, you should not rely on these forward-looking statements as representing the company's views as of any date subsequent the date such statements are made.